Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 12/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | PRF1 | P14222 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2508327 | 0.83 | HDAC6 (0.44) | HDAC6GRM5KDM4EALDH1A1LMNA | |
| SCHEMBL2505981 | 0.82 | HDAC6 (0.44) | HDAC6GRM5ALDH1A1IDH1PRF1 | |
| SCHEMBL2503427 | 0.80 | HDAC6 (0.43) | HDAC6GRM5KDM4EALDH1A1LMNA | |
| SCHEMBL2506687 | 0.77 | GRM5 (0.40) | HDAC6GRM5KDM4EALDH1A1LMNA | |
| SCHEMBL2506138 | 0.77 | GRM5 (0.46) | GRM5KDM4EALDH1A1LMNAGAA | |
| SCHEMBL2509397 | 0.76 | HDAC6 (0.44) | HDAC6GRM5ALDH1A1IDH1PRF1 | |
| SCHEMBL2504269 | 0.76 | HDAC6 (0.44) | HDAC6GRM5LMNAIDH1 | |
| SCHEMBL2514240 | 0.75 | IDH1 (0.40) | HDAC6GRM5KDM4EALDH1A1LMNA | |
| SCHEMBL2504281 | 0.73 | HDAC6 (0.42) | HDAC6GRM5PRF1 | |
| SCHEMBL2505087 | 0.73 | GRM5 (0.42) | GRM5KDM4EALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314120-B2 | Small molecule potentiators of metabotropic glutamate receptors | ABBOTT GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | claimed |
| US-8314120-B2 | Small molecule potentiators of metabotropic glutamate receptors | ABBOTT GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | disclosed |
| US-20110245247-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245247-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRIN2C, GRM3, GRM2 | HDAC6 2622/4885BRAF 4459/4885GRM5 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.